CYCLERION THERAPEUTICS CYCN 深 沪
交易中 03-30 11:40:22 美东时间
1.43
-0.075
-4.98%
华盛通- 最 高1.455
- 今 开1.45
- 成交量 1.54万股
- 最 低 1.40
- 昨 收 1.505
- 总市值 561.32万
- 52周最高 3.79
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.0266
- 委 比 83.04%
- 总股本 392.53万
- 历史最高 296.60
- 量 比 1.78
- 振 幅 3.65%
- 历史最低 1.0266
- 每 手 1
- 风险率 0.71%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board
Cyclerion Therapeutics has received positive regulatory feedback from the FDA for its Phase 2 POC study of CYC-126 for treatment-resistant depression (TRD). CYC-126, an anesthetic-based therapy using real-time EEG feedback, aims to address TRD through individualized, precision delivery. The FDA supports the study design, leveraging approved anesthetics, allowing Cyclerion to remain on track to initiate the trial in late 2026. Additionally, the co...
02-17 12:00
Watching Cyclerion Therapeutics; Zacks Small-Cap Research Gives Stock $8.00 Price Valuation
https://s27.q4cdn.com/906368049/files/News/2026/Zacks_SCR_Research_02022026_CYCN_Bautz.pdf
02-03 01:07
Market-Moving News for January 6th
AEVA: 40% | Aeva Technologies' Frequency Modulated Continuous Wave 4D LiDAR Technology Selected For The NVIDIA Drive Hyperion Autonomous Vehicle Reference Platform; Aeva And NVIDIA Will Collaborate To Integrate
01-06 20:11
Cyclerion Therapeutics Collaborates With Medsteer To Integrate Medsteer's Technology Into Cyclerion's CYC-126 Program
Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), a biopharmaceutical company pioneering neuropsychiatric therapies, today announced an application-specific, exclusive collaboration with Medsteer, a leader in anesthetic
01-06 05:02
Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression
Cyclerion Therapeutics announces a strategic collaboration with Medsteer to advance its CYC-126 program, a novel anesthetic-based therapy for treatment-resistant depression (TRD). The partnership aims to integrate Medsteer's closed-loop anesthetic delivery technology into Cyclerion's platform, enhancing precision and real-time patient feedback. Cyclerion plans to initiate a Phase 2 proof-of-concept study in late 2026. A webcast featuring Dr. Huss...
01-05 21:01
Cyclerion Receives Milestone Payment from Akebia
Cyclerion Therapeutics ( ($CYCN) ) has issued an update. On December 1, 2025, A...
2025-12-02 06:28
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers MSP Recovery (NASDAQ:MSPR) shares rose 93.0% to $0.61 during Tuesday's...
2025-11-11 20:07
BUZZ-Cyclerion Therapeutics jumps on MIT deal to develop depression drug
** Shares of drug developer Cyclerion Therapeutics CYCN.O rise 43% to $4.33 premarket ** Co said late on Tuesday it is relaunching as a neuropsychiatric-focused firm after signing a licensing deal wit...
2025-09-24 18:26
Cyclerion Therapeutics Relaunches with Neuropsychiatric Focus
Cyclerion Therapeutics ( ($CYCN) ) has issued an update. On September 19, 2025,...
2025-09-24 05:13
快讯 | Cyclerion Therapeutics - 根据许可协议，Mit有资格获得高达440万美元的里程碑付款 - SEC文件
Cyclerion Therapeutics - Under License Agreement, Mit Eligible for up to $4.4 M...
2025-09-24 04:19
